Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 385

Companies Banking on Anti-Smoking Trend

by H.S. AyoubBioHealth Investor.com During the November elections three states, Ohio, Arizona and Nevada, passed tight smoking bans. Arizona’s anti-smoking laws will be enforced in May, Ohio is proceeding through the final legal drafts,…

Douglas A. McIntyre · 20 years ago

Monday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology NEURO-HITECH INC +17.36% LEV PHARMACEUTICALS +11.18% OBAGI MEDICAL +9.16% GENVEC INC +7.84% ACHILLION PHARMACEUT +6.71% Diagnostic Substances SCOLR PHARMA INC +8.00% LEXICON GENETICS I +6.97% ASPENBIO PHARMA INC +6.12% ABAXIS…

Douglas A. McIntyre · 20 years ago

Biotechs Ahead of Pharmas after All?

by H.S. AyoubBioHealth Investor.com In an earlier article, I reviewed Pisano’s book Science Business: the Promise, the Reality, and the Future of Biotech, in which the Harvard business professor provides compelling evidence showcasing the…

Douglas A. McIntyre · 20 years ago

Cramer Defends Amgen (AMGN)

Another ‘Fallen Angel’ from Cramer on CNBC’s MAD MONEY is Amgen (AMGN-NASDAQ) after it got crushed last week.  He said this is much to do about nothing.  The headline risk was that Aranesp was…

Douglas A. McIntyre · 20 years ago

Bristol-Myers’ Buyout Price? $28.35 Or Less to Options Prices

The talk of IF Bristol-Myers Squibb (BMY-NYSE) is really going to be gobbled up by Sanofi-Aventis (SNY-NYSE/ADR) hasn’t gone away, but the dust is settling.  We covered the ‘media reports’ and what it would…

Douglas A. McIntyre · 20 years ago

Government Contract Could Set Hollis-Eden Stock Soaring

from BioHealth Investor The upcoming week will be a big one for Hollis Eden Pharmaceuticals (HEPH), a company I’ve written about previously. The company was founded in 1992 and they’ve not advanced a single…

Douglas A. McIntyre · 20 years ago

Some Thoughts On JNJ and Abbott Labs

By Vitaliy Katsenelson, CFA    January 26, 2007 It seems that 2007 should be a brighter year for Johnson & Johnson (NYSE JNJ).  In 2006 the company faced major drug expirations which dampened revenue…

Douglas A. McIntyre · 20 years ago

Friday’s Top Biotech and Medical Stocks

Biotechnology FERMAVIR PHARMACEUTL +19.05% POLYMEDIX INC +14.29% KOSAN BIOSCIENCES +11.11% BIONOVO INC +10.04% NEURO-HITECH INC +9.01% Diagnostic Substances ABAXIS INC +21.00% INFINITY PHARMACEUTI +5.15% GENE LOGIC INC +4.58% PONIARD PHARMA +4.46% IDEXX LABS +3.93%…

Douglas A. McIntyre · 20 years ago

IBD Weekly Top Ranked Medical Stocks

The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative Strength by Investor’s Business Daily (1/27/06) scores out of 100 (last week’s rank, change in score): 1(1)…

Douglas A. McIntyre · 20 years ago

Three Biotech Drugs Have Potential to Treat Polonium-210 Radiation

by H.S. AyoubBioHealth Investor.com After the murder of former Russian intelligence agent Alexander Litvinenko government agencies began to worry about possible future terrorist attacks using the radioactive element polonium-210. Both the National Institute of…

Douglas A. McIntyre · 20 years ago

Thursday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology FERMAVIR PHARMACEUTL +17.60% OBAGI MEDICAL +8.72% XTL BIOPHARMACEUTICA +7.31% CYTORI THERAPEUTICS +7.16% MEMORY PHARMACEUTICA +4.64% Diagnostic Substances AVALON PHARMACEUTIC +4.60% ICAGEN, INC. +3.70% PRESSURE BIOSCIENC +2.50% COLEY PHARMACEUTICAL +1.76% ASPENBIO…

Douglas A. McIntyre · 20 years ago

Why Does Proctor & Gamble Need a Dental Laser?

From BioHealth Investor by H.S. AyoubBioHealth Investor.com BioLase Technology (BLTI) announced early Thursday that the company had signed a definitive agreement with Proctor & Gamble (PG). Under the terms of the agreement PG will…

Douglas A. McIntyre · 20 years ago

Amgen Treated Like a Normal Drug Stock

Amgen (AMGN-NASDAQ) posted EPS of $0.90, but $0.71 on GAAP EPS.  Revenues were $3.73 Billion versus $3.7 Billion estimates.  Revenues are projected for $15.4 to $16 Billion for 2007 and adjusted EPS put for…

Douglas A. McIntyre · 20 years ago

Wednesday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology NEUROBIOLOGICAL TECH +8.26% INTROGEN THERAPEU +7.89% CYTRX CP +7.86% IMMUNE RESPONSE CORP +6.16% EMERGENT BIOSOLUTION +6.12% Diagnostic Substances COLEY PHARMACEUTICAL +10.26% RG GLBL LIFESTYLS +7.58% PALATIN TECH INC +5.26% IMMUNOMEDICS…

Douglas A. McIntyre · 20 years ago